Ascendis Pharma A/S (ASND) Reports Disappointing Q3 Results
Ascendis Pharma A/S (ASND) reports Q3 2025 results, missing EPS and revenue expectations.
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. The firm produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The firm operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
Latest news, analyst ratings, earnings reports, dividends, insider trades, and market analysis for Ascendis Pharma A/S.
Last Updated: Nov 8, 2025, 3:25 PM · Source: Finnhub.io